Skip to main content
. 2020 Feb 6;13(3):440–450. doi: 10.1111/cts.12736

Figure 4.

Figure 4

A comparison of both the royalty and integrated business models used by private companies in the biomedical industry. The pros and cons are listed with the assumption that they are for a start‐up company in regenerative medicine.